Evo Fund Takes 41.54% Stake in Ribomics (4591) | Large Shareholding Report

A large shareholding report (EDINET filing) reveals that Evo Fund has acquired a 41.54% stake in Ribomics Inc. (4591). The acquisition was made by an event-driven investment fund affiliated with Evolution Japan.

The filing was disclosed on August 18, 2025, with an estimated acquisition value of approximately ¥2.51 billion. Since no prior disclosure by the same filer was found within the past 400 days, this represents a substantive new acquisition or major resumption of holdings. The 41.54% stake positions Evo Fund as a substantial shareholder with effective control-level influence over the company.

The fund's substantial acquisition reflects an investment decision recognizing significant business value in Ribomics. Given the event-driven nature of the fund's strategy, the shareholding size suggests an approach oriented toward management engagement and expanding influence over corporate decisions.

*Speculation: The fund's near-majority stake may represent an investment aimed at establishing itself as a key stakeholder with material influence over future management composition and strategic decisions at the company.